Urticaria is a highly prevalent inflammatory skin disorder, typically presenting as itchy wheals of various sizes, accompanied by erythema of the surrounding skin. There are two currently known drivers of CSU pathogenesis: autoallergy with IgE autoantibody involvement, and autoimmunity with IgG autoantibody involvement. For all chronic urticaria, the standard first-line treatments are second generation H1 antihistamines.
From a pathological standpoint, the different subtypes of CU are inadequately defined and lack reliable diagnostic biomarkers, making the design of more targeted therapeutic agents difficult. Improved efforts in pathology research and drug development are needed to meet the needs of CU patients across the world. This white paper discusses how to overcome common challenges in clinical research for Urticaria therapies.
Get Your Copy Now
Fields marked with * are required.